Co-Op – Cardiovascular Translational Research
Fall 2024
Posted on 1/17/2024
INACTIVE
Bristol-Myers Squibb

10,001+ employees

Develops therapies for serious diseases using translational medicine.
Company Overview
Bristol Myers Squibb stands out as a leader in the biopharma industry, with a diverse team of experts dedicated to transforming patients' lives through scientific advancements in areas like oncology, hematology, immunology, cardiovascular disease, and fibrosis. The company's commitment to health equity, demonstrated through the Bristol Myers Squibb Foundation, and its use of translational medicine and data analytics to personalize patient care, set it apart from competitors. The culture at BMS encourages growth and offers opportunities that are unique in scale and scope, making it an inspiring place to work.
Data & Analytics
Biotechnology

Company Stage

N/A

Total Funding

$33.7B

Founded

1887

Headquarters

Lawrence Township, New Jersey

Growth & Insights
Headcount

6 month growth

3%

1 year growth

3%

2 year growth

-3%
Locations
Daly City, CA, USA
Experience Level
Intern
Requirements
  • Current graduate student with good standing in biological science graduate program; a demonstrated emphasis in translational biomarkers (preferred)
  • Completion of at least first year in an accredited graduate degree program
  • Availability for full-time employment (40 hrs/week) throughout 6-month program period
  • Experience in wet lab experimentation, analysis & interpretation of results is required
  • Interpersonal and collaboration skills, including the willingness and ability to foster working relationships with a range of stakeholders
Responsibilities
  • Actively contribute to translational project which is aligned with Cardiovascular Translational Research objectives and participate in BMS Co-op program requirements
  • Responsibilities may include laboratory work, literature/data review, and/or computational analyses
  • Present Co-op project at the Cardiovascular Translational Research weekly lab meetings and at the conclusion of the program to the Translational Early Development Team